Improving influenza virus backbones by including terminal regions of MDCK-adapted strains on hemagglutinin and neuraminidase gene segments

Vaccine

Volumn 31, Issue 42, 2013, Pages 4736-4743

  Gomila, Raúl C ^a   Suphaphiphat, Pirada ^a   Judge, Casey ^a   Spencer, Terika ^a   Ferrari, Annette ^a   Wen, Yingxia ^a   Palladino, Giuseppe ^a   Dormitzer, Philip R ^a   Mason, Peter W ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Chimeras; Hemagglutinin; Influenza; Reverse genetics; Vaccine seeds

Indexed keywords

CHIMERIC PROTEIN; HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; VACCINE SEED VIRUS; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG MANUFACTURE; GENE SEQUENCE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; MDCK CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REPRODUCIBILITY; REVERSE GENETICS; TERMINAL SEQUENCE; VIROGENESIS; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS STRAIN; WILD TYPE;

CHIMERAS; HEMAGGLUTININ; INFLUENZA; REVERSE GENETICS; VACCINE SEEDS;

ADAPTATION, BIOLOGICAL; ANIMALS; CELL LINE; DOGS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; NEURAMINIDASE; REVERSE GENETICS; TECHNOLOGY, PHARMACEUTICAL; VIRAL PROTEINS; VIRUS CULTIVATION;

EID: 84884206086     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.026     Document Type: Article

References (34)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc 2003, 289(2):179-186.
2. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56(1):152-179.
3. Neumann G., Kawaoka Y. The first influenza pandemic of the new millennium. Influenza Other Respir Viruses 2011, 5(3):157-166.
4. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201.
5. Fulvini A.A., Ramanunninair M., Le J., Pokorny B.A., Arroyo J.M., Silverman J., et al. Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production. PLoS One 2011, 6(6):e20823.
6. Nobusawa E., Ishihara H., Morishita T., Sato K., Nakajima K. Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology 2000, 278(2):587-596.
7. Voeten J.T., Brands R., Palache A.M., van Scharrenburg G.J., Rimmelzwaan G.F., Osterhaus A.D., et al. Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. Vaccine 1999, 17(15/16):1942-1950.
8. Kodihalli S., Justewicz D.M., Gubareva L.V., Webster R.G. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol 1995, 69(8):4888-4897.
9. Stevens J., Corper A.L., Basler C.F., Taubenberger J.K., Palese P., Wilson I.A. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (New York, NY) 2004, 303(5665):1866-1870.
10. Suphaphiphat P., Franti M., Hekele A., Lilja A., Spencer T., Settembre E., et al. Mutations at positions 186 and 194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve replication in cell culture and eggs. Virol J 2010, 7:157.
11. Dormitzer P.R., Suphaphiphat P., Gibson D.G., Wentworth D.E., Stockwell T.B., Algire M.A., et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013, 5(185):185ra68.
12. Okuno Y., Tanaka K., Baba K., Maeda A., Kunita N., Ueda S. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 1990, 28(6):1308-1313.
13. Network W.G.I.S. Manual for the laboratory diagnosis and virological surveillance of influenza 2011, Available from: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf.
14. Harvey R., Guilfoyle K.A., Roseby S., Robertson J.S., Engelhardt O.G. Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules. J Virol 2011, 85(12):6086-6090.
15. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9(7):671-675.
16. Harvey R., Nicolson C., Johnson R.E., Guilfoyle K.a., Major D.L., Robertson J.S., et al. Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules. Vaccine 2010, 28(50):8008-8014.
17. Adamo J.E., Liu T., Schmeisser F., Ye Z. Optimizing viral protein yield of influenza virus strain A/Vietnam/1203/2004 by modification of the neuraminidase gene. J Virol 2009, 83(9):4023-4029.
18. Pan W., Dong Z., Meng W., Zhang W., Li T., Li C., et al. Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34. Hum Vaccin Immunother 2012, 8(2):252-259.
19. Jing X., Phy K., Li X., Ye Z. Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains. Vaccine 2012, 30(28):4144-4152.
20. Neumann G., Brownlee G.G., Fodor E., Kawaoka Y. Orthomyxovirus replication, transcription, and polyadenylation in biology of negative strand RNA viruses: the power of reverse genetics 2004, 121-143. Y. Kawaoka (Ed.).
21. Hutchinson E.C., von Kirchbach J.C., Gog J.R., Digard P. Genome packaging in influenza A virus. J Gen Virol 2010, 91(Pt 2):313-328.
22. Fujii Y., Goto H., Watanabe T., Yoshida T., Kawaoka Y. Selective incorporation of influenza virus RNA segments into virions. Proc Natl Acad Sci USA 2003, 100(4):2002-2007.
23. Brooke C.B., Ince W.L., Wrammert J., Ahmed R., Wilson P.C., Bennink J.R., et al. Most influenza A virions fail to express at least one essential viral protein. J Virol 2013, 87(6):3155-3162.
24. Fournier E., Moules V., Essere B., Paillart J.C., Sirbat J.D., Cavalier A., et al. Interaction network linking the human H3N2 influenza A virus genomic RNA segments. Vaccine 2012, 30(51):7359-7367.
25. Noda T., Sugita Y., Aoyama K., Hirase A., Kawakami E., Miyazawa A., et al. Three-dimensional analysis of ribonucleoprotein complexes in influenza A virus. Nat Commun 2012, 3:639.
26. Marsh G.A., Hatami R., Palese P. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol 2007, 81(18):9727-9736.
27. Muramoto Y., Takada A., Fujii K., Noda T., Iwatsuki-Horimoto K., Watanabe S., et al. Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J Virol 2006, 80(5):2318-2325.
28. Marsh G.A., Rabadan R., Levine A.J., Palese P. Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging. J Virol 2008, 82(5):2295-2304.
29. Barman S., Adhikary L., Chakrabarti A.K., Bernas C., Kawaoka Y., Nayak D.P. Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza A virus neuraminidase in raft association and virus budding. J Virol 2004, 78(10):5258-5269.
30. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003, 41(2):742-750.
31. Kundu A., Avalos R.T., Sanderson C.M., Nayak D.P. Transmembrane domain of influenza virus neuraminidase: a type II protein, possesses an apical sorting signal in polarized MDCK cells. J Virol 1996, 70(9):6508-6515.
32. Scheiffele P., Roth M.G., Simons K. Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. EMBO J 1997, 16(18):5501-5508.
33. Ali A., Avalos R.T., Ponimaskin E., Nayak D.P. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol 2000, 74(18):8709-8719.
34. Harvey R., Wheeler J.X., Wallis C.L., Robertson J.S., Engelhardt O.G. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 2008, 26(51):6550-6554.